|
| Category | FY | Funding IC | Project Number | Sub Project # | Project Title | PI Name | Org Name | State / Country | Amount |
|
Hepatitis
|
2012
|
OD
|
5R01DA026727-02
|
|
HIV, HCV and Liver Disease Among Injection Drug Users in Chennai, India
|
MEHTA, SHRUTI
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$580,907
|
|
Hepatitis
|
2012
|
NIDDK
|
1K24DK092336-01
|
|
Patient-oriented and effectiveness research in chronic liver disease
|
KIM, W. RAY
|
MAYO CLINIC
|
MN
|
$126,779
|
|
Hepatitis
|
2012
|
NIDA
|
1R34DA031063-01A1
|
|
DVD-based HIV/HCV Intervention for Drug-Involved Latino Criminal Justice Clients
|
IBANEZ, GLADYS
|
UNIVERSITY OF DELAWARE
|
DE
|
$275,400
|
|
Hepatitis
|
2012
|
NIAID
|
5R01AI078195-04
|
|
Chemokines in Autoimmune Hepatitis
|
GORHAM, JAMES
|
DARTMOUTH COLLEGE
|
NH
|
$391,795
|
|
Hepatitis
|
2012
|
NCI
|
5R01CA132962-03
|
|
A Genetic Screen for HCC Genes
|
LARGAESPADA, DAVID
|
UNIVERSITY OF MINNESOTA TWIN CITIES
|
MN
|
$302,919
|
|
Hepatitis
|
2012
|
NIAID
|
5R01AI060021-22
|
|
Molecular biology of coronavirus induced demyelination
|
WEISS, SUSAN
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$302,998
|
|
Hepatitis
|
2012
|
OD
|
9U42OD014838-11
|
|
Chimpanzee Biomedical Research Program Limited Competition (U42)
|
BLANCHARD, JAMES
|
UNIVERSITY OF LOUISIANA AT LAFAYETTE
|
LA
|
$1,858,987
|
|
Hepatitis
|
2012
|
NIAID
|
5R21AI092074-02
|
|
Transgenic mouse models of HCV infection and replication
|
JIANG, JIEYUN
|
UNIVERSITY OF KENTUCKY
|
KY
|
$222,750
|
|
Hepatitis
|
2012
|
NIAID
|
5R01AI075099-05
|
|
Role of HCV p7 and NS2 in infectious virus production
|
RICE, CHARLES
|
ROCKEFELLER UNIVERSITY
|
NY
|
$414,092
|
|
Hepatitis
|
2012
|
OD
|
8K26OD012218-04
|
|
Mouse Immunopathology
|
LIU, CHEN
|
UNIVERSITY OF FLORIDA
|
FL
|
$161,563
|
|
Hepatitis
|
2012
|
NIAID
|
5R01AI073335-05
|
|
RNA-dependent RNA Synthesis by the Hepatitis C Virus
|
KAO, CHENG
|
INDIANA UNIVERSITY BLOOMINGTON
|
IN
|
$332,912
|
|
Hepatitis
|
2012
|
NIAID
|
5R01AI087917-03
|
|
HCV NS4B: Translating molecular virology into novel antiviral therapies
|
GLENN, JEFFREY
|
STANFORD UNIVERSITY
|
CA
|
$396,363
|
|
Hepatitis
|
2012
|
NIAID
|
5R01AI020001-29
|
|
Pathogenesis of Liver Disease in Hepatitis
|
CHISARI, FRANCIS
|
SCRIPPS RESEARCH INSTITUTE
|
CA
|
$644,514
|
|
Hepatitis
|
2012
|
NIAID
|
5R37AI047365-13
|
|
Structure and Function of the Hepatitis C Virus Genome
|
SARNOW, PETER
|
STANFORD UNIVERSITY
|
CA
|
$435,131
|
|
Hepatitis
|
2012
|
NIAID
|
5R37AI047367-13
|
|
HCV-specific T cell response
|
WALKER, CHRISTOPHER
|
RESEARCH INST NATIONWIDE CHILDREN'S HOSP
|
OH
|
$662,172
|
|
Hepatitis
|
2012
|
OD
|
5R37AI047367-13
|
|
HCV-specific T cell response
|
WALKER, CHRISTOPHER
|
RESEARCH INST NATIONWIDE CHILDREN'S HOSP
|
OH
|
$43,792
|
|
Hepatitis
|
2012
|
NIAID
|
5R01AI071084-04
|
|
Probing the antibody response to HCV to facilitate rational immunogen design
|
BURTON, DENNIS
|
SCRIPPS RESEARCH INSTITUTE
|
CA
|
$621,118
|
|
Hepatitis
|
2012
|
NIAID
|
5R01AI069000-07
|
|
Roles for microRNA-122 in hepatitis C virus RNA amplification
|
SARNOW, PETER
|
STANFORD UNIVERSITY
|
CA
|
$391,459
|
|
Hepatitis
|
2012
|
NIAID
|
5R01AI087746-03
|
|
Cyclophilins, Cyclophilin Inhibitors and Hepatitis C
|
GALLAY, PHILIPPE
|
SCRIPPS RESEARCH INSTITUTE
|
CA
|
$470,003
|
|
Hepatitis
|
2012
|
NCI
|
5R01CA126807-05
|
|
HCV genetic variation and hepatocellular carcinoma
|
TAVIS, JOHN
|
SAINT LOUIS UNIVERSITY
|
MO
|
$266,288
|
|
Hepatitis
|
2012
|
NIEHS
|
5R01ES005116-21
|
|
Biological Markers of Aflatoxin Exposure and Methylation
|
SANTELLA, REGINA
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
NY
|
$399,466
|
|
Hepatitis
|
2012
|
NICHD
|
5R01HD062489-02
|
|
Pediatric Adverse Drug Reactions in NASH
|
CHERRINGTON, NATHAN
|
UNIVERSITY OF ARIZONA
|
AZ
|
$321,938
|
|
Hepatitis
|
2012
|
NIDDK
|
5R01DK090313-02
|
|
Hepatic Steatosis and ER Stress-Inducible Transcription Factor CREBH
|
ZHANG, KEZHONG
|
WAYNE STATE UNIVERSITY
|
MI
|
$330,600
|
|
Hepatitis
|
2012
|
NIAID
|
5R01AI040696-15
|
|
Regulation of HBV Replication by the Immune System
|
GUIDOTTI, LUCA
|
SCRIPPS RESEARCH INSTITUTE
|
CA
|
$464,322
|
|
Hepatitis
|
2012
|
NIAID
|
5R01AI088001-04
|
|
Antiviral potential of helicase inhibitors
|
FRICK, DAVID
|
UNIVERSITY OF WISCONSIN MILWAUKEE
|
WI
|
$365,558
|
|
Hepatitis
|
2012
|
NIAID
|
5R01AI069142-06
|
|
Immune Mechanisms of HCV Persistence and Pathogenesis
|
SUN, JIAREN
|
UNIVERSITY OF TEXAS MEDICAL BR GALVESTON
|
TX
|
$326,663
|
|
Hepatitis
|
2012
|
NIDDK
|
5K23DK083439-03
|
|
Non-invasive evaluation of Non-alcoholic Steatohepatitis
|
LAI, MICHELLE
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
MA
|
$177,444
|
|
Hepatitis
|
2012
|
NIAID
|
5R01AI087925-03
|
|
Molecular determinants of hepatitis C virus assembly
|
LINDENBACH, BRETT
|
YALE UNIVERSITY
|
CT
|
$409,613
|
|
Hepatitis
|
2012
|
NIDDK
|
5R01DK077704-05
|
|
Viral Hepatitis C and Lipid Homeostasis
|
SIDDIQUI, ALEEM
|
UNIVERSITY OF CALIFORNIA AT SAN DIEGO
|
CA
|
$321,779
|
|
Hepatitis
|
2012
|
NIDA
|
5R01DA012568-14
|
|
Incidence of HIV Infection in a Cohort of IV Drug Users
|
MEHTA, SHRUTI
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$1,002,081
|
|
Hepatitis
|
2012
|
NIEHS
|
5R01ES016313-05
|
|
The Environment as a Variable to Calibrate Mouse Models of Human Disease
|
ESSIGMANN, JOHN
|
MASSACHUSETTS INSTITUTE OF TECHNOLOGY
|
MA
|
$565,382
|
|
Hepatitis
|
2012
|
NIEHS
|
5K01ES017105-03
|
|
Ubiquitous pollutant acrolein inhibits IFN?? antiviral signaling: relevance to HC
|
JOSHI-BARVE, SWATI
|
UNIVERSITY OF LOUISVILLE
|
KY
|
$131,085
|
|
Hepatitis
|
2012
|
NIAID
|
5K08AI077713-05
|
|
HCV diversity and resistance analyzed by DNA bar coding and pyrosequencing
|
WANG, GARY
|
UNIVERSITY OF FLORIDA
|
FL
|
$131,652
|
|
Hepatitis
|
2012
|
NINDS
|
5R01NS041249-11
|
|
Chemokines and Viral-Induced Neurologic Disease
|
LANE, THOMAS
|
UNIVERSITY OF CALIFORNIA IRVINE
|
CA
|
$321,113
|
|
Hepatitis
|
2012
|
NCI
|
5R01CA057973-19
|
|
Structure and function of the HCV RNA replicase
|
RICE, CHARLES
|
ROCKEFELLER UNIVERSITY
|
NY
|
$376,233
|
|
Hepatitis
|
2012
|
NIDA
|
5R01DA029512-03
|
|
Integrated vs. Separate Care for Hepatitis C, Substance Abuse, and HIV Prevention
|
EDLIN, BRIAN
|
SUNY DOWNSTATE MEDICAL CENTER
|
NY
|
$693,247
|
|
Hepatitis
|
2012
|
NIGMS
|
5R01GM081420-04
|
|
Characterizing RNA-metal binding by Raman spectroscopy
|
CAREY, PAUL
|
CASE WESTERN RESERVE UNIVERSITY
|
OH
|
$307,172
|
|
Hepatitis
|
2012
|
NIDA
|
5R25DA013582-12
|
|
Clinical Addiction Research and Education Program
|
SAMET, JEFFREY
|
BOSTON MEDICAL CENTER
|
MA
|
$369,491
|
|
Hepatitis
|
2012
|
NIDDK
|
1R01DK093568-01
|
|
Impact of Fructose on Metabolism, Energy Homeostasis and MR biomarkers in NAFLD
|
SOHER, BRIAN
|
DUKE UNIVERSITY
|
NC
|
$296,900
|
|
Hepatitis
|
2012
|
NCI
|
1R01CA164029-01
|
|
Murine Model of HCV-Associated Human Liver Cancer
|
LEMON, STANLEY
|
UNIVERSITY OF N CAROLINA AT CHAPEL HILL
|
NC
|
$470,695
|
|
Hepatitis
|
2012
|
NIAID
|
1R01AI097318-01
|
|
Underlying Mechanisms of ApoE in HCV Infection and Assembly
|
LUO, GUANGXIANG
|
UNIVERSITY OF KENTUCKY
|
KY
|
$371,250
|
|
Hepatitis
|
2012
|
NIGMS
|
1R01GM100071-01
|
|
Nanofluidic Devices for Studying Assembly of Single Virus Particles
|
JACOBSON, STEPHEN
|
INDIANA UNIVERSITY BLOOMINGTON
|
IN
|
$284,517
|
|
Hepatitis
|
2012
|
NIDA
|
5R01DA024598-05
|
|
Social networks and HIV risk among rural drug users
|
HAVENS, JENNIFER
|
UNIVERSITY OF KENTUCKY
|
KY
|
$326,837
|
|
Hepatitis
|
2012
|
NIDDK
|
5R01DK088114-02
|
|
Effects of recombinant human leptin in nonalcoholic fatty liver disease (NAFLD)
|
ORAL, ELIF
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
MI
|
$338,213
|
|
Hepatitis
|
2012
|
NCI
|
5R01CA120719-04
|
|
Markers for HCV-related HCC: plasma profiling, targeted strategies and validation
|
BERETTA, LAURA
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
WA
|
$354,244
|
|
Hepatitis
|
2012
|
NIDDK
|
1R01DK088831-01A1
|
|
Intestinal bacterial metagenome in pediatric NAFLD
|
SALZMAN, NITA
|
MEDICAL COLLEGE OF WISCONSIN
|
WI
|
$1,499,969
|
|
Hepatitis
|
2012
|
NIDA
|
5R01DA024553-04
|
|
Treatment Study Using Depot Naltrexone(1/6)Philadelphia Coord/Data Mgmt Site
|
O'BRIEN, CHARLES
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$560,640
|
|
Hepatitis
|
2012
|
NIDDK
|
5R01DK085252-02
|
|
LPS binding to TLR4 regulates hepatic stellate cell activation and fibrosis
|
SEKI, EKIHIRO
|
UNIVERSITY OF CALIFORNIA AT SAN DIEGO
|
CA
|
$336,672
|
|
Hepatitis
|
2012
|
NIMHD
|
5R24MD002756-05
|
|
CBPR on Hepatitis B Intervention for Underserved Korean Americans
|
MA, GRACE
|
TEMPLE UNIVERSITY
|
PA
|
$561,701
|
|
Hepatitis
|
2012
|
NIDA
|
1K24DA034621-01
|
|
Patient Oriented Research in Hepatitis C-infected Injection Drug Users
|
SULKOWSKI, MARK
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$118,638
|
|
Hepatitis
|
2012
|
NIDDK
|
5K23DK085150-02
|
|
Non-Alcoholic Fatty Liver Disease and Obstructive Sleep Apnea: Mechanistic Links
|
SUNDARAM, SHIKHA
|
UNIVERSITY OF COLORADO DENVER
|
CO
|
$179,258
|
|
Hepatitis
|
2012
|
NIAID
|
1R21AI097809-01
|
|
Elucidating the role of the NPC1L1 cholesterol uptake receptor in HCV infection
|
UPRICHARD, SUSAN
|
UNIVERSITY OF ILLINOIS
|
IL
|
$162,041
|
|
Hepatitis
|
2012
|
NIAID
|
1K08AI097322-01
|
|
Antivirals for Hepatitis C Targeting Phosphoinositide Metabolism
|
GELMAN, MICHAEL
|
STANFORD UNIVERSITY
|
CA
|
$133,191
|
|
Hepatitis
|
2012
|
NIAID
|
1R21AI097858-01
|
|
Nonstructural 4B Protein and Hepatitus C Virus Production
|
KONAN, KOUACOU
|
ALBANY MEDICAL COLLEGE
|
NY
|
$237,000
|
|
Hepatitis
|
2012
|
NCI
|
5R01CA039416-27
|
|
Molecular Mechanisms of Chemoprevention: NRF2 Signaling
|
KENSLER, THOMAS
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$486,646
|
|
Hepatitis
|
2012
|
NIAID
|
5R01AI091707-02
|
|
Type I interferon-stimulated genes and the antiviral immune response
|
RICE, CHARLES
|
ROCKEFELLER UNIVERSITY
|
NY
|
$422,500
|
|
Hepatitis
|
2012
|
NIDDK
|
5R01DK087977-02
|
|
The Role of Mitochondrial Dysfunction in Non-Alcoholic Fatty Liver Disease
|
BROWNING, JEFFREY
|
UNIV OF TX SW MED CTR-DALLAS
|
TX
|
$417,866
|
|
Hepatitis
|
2012
|
NIAID
|
5R44AI074256-03
|
|
Chemical Stabilization of shRNAs and their development as hepatitis C drugs
|
JOHNSTON, BRIAN
|
SOMAGENICS, INC.
|
CA
|
$970,401
|
|
Hepatitis
|
2012
|
NIDDK
|
5R01DK074673-05
|
|
Impact of Hepatitis C on Insulin Sensitivity and Insulin Secretion in Latinos
|
KHALILI, MANDANA
|
UNIV OF CALIFORNIA AT SAN FRANCISCO
|
CA
|
$428,949
|
|
Hepatitis
|
2012
|
NCI
|
1R21CA159132-01A1
|
|
Synergistic innate immune activation and cell killing by RIG-I ligands in HCV-HCC
|
GEHRKE, LEE
|
MASSACHUSETTS INSTITUTE OF TECHNOLOGY
|
MA
|
$209,453
|
|
Hepatitis
|
2012
|
NCI
|
1R01CA158271-01A1
|
|
Hepatocyte Nox proteins in the pathogenesis of hepatocellular carcinoma
|
CHOI, JINAH
|
UNIVERSITY OF CALIFORNIA, MERCED
|
CA
|
$311,106
|
|
Hepatitis
|
2012
|
NIAID
|
2R01AI060561-08
|
|
Immune complexes: Origins and effects in HCV infection
|
DUSTIN, LYNN
|
ROCKEFELLER UNIVERSITY
|
NY
|
$423,750
|
|
Hepatitis
|
2012
|
NIMH
|
5F31MH087226-03
|
|
Emotion and Relationships Underlying HIV/HCV Risk Among Incarcerated Women
|
YARD, SAMANTHA
|
UNIVERSITY OF WASHINGTON
|
WA
|
$42,232
|
|
Hepatitis
|
2012
|
NCI
|
5R21CA152514-02
|
|
HCV Strain Variation and HCC
|
BRANCH, ANDREA
|
MOUNT SINAI SCHOOL OF MEDICINE
|
NY
|
$184,331
|
|
Hepatitis
|
2012
|
NIAID
|
5R01AI074982-05
|
|
Molecular Mechanism of Hepadnavirus Persistence
|
HU, JIANMING
|
PENNSYLVANIA STATE UNIVERSITY
|
PA
|
$297,189
|
|
Hepatitis
|
2012
|
NIAID
|
5K08AI075031-05
|
|
The Pathogenesis of Autoimmunity in Hepatitis C Virus Infection
|
CHARLES, EDGAR
|
ROCKEFELLER UNIVERSITY
|
NY
|
$140,400
|
|
Hepatitis
|
2012
|
NIDDK
|
5R01DK088076-03
|
|
Role of microRNA-122 in hepatocarcinogenesis using conditional knock out mice
|
GHOSHAL, KALPANA
|
OHIO STATE UNIVERSITY
|
OH
|
$313,273
|
|
Hepatitis
|
2012
|
NIMH
|
5R01MH090250-03
|
|
Vulnerability to major depression: The role of delta sleep in patients receiving
|
LOTRICH, FRANCIS
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$315,596
|
|
Hepatitis
|
2012
|
NIAAA
|
1R21AA020351-01A1
|
|
Dissecting the Role of Unfolded Protein Response in Alcoholic Liver Disease
|
QI, LING
|
CORNELL UNIVERSITY
|
NY
|
$182,875
|
|
Hepatitis
|
2012
|
NIDDK
|
5R01DK072017-06
|
|
Obesity and Hepatic Steatosis
|
PAGLIASSOTTI, MICHAEL
|
COLORADO STATE UNIVERSITY-FORT COLLINS
|
CO
|
$254,392
|
|
Hepatitis
|
2012
|
NINDS
|
5F31NS070706-03
|
|
Diffusion Tensor Imaging and Neuropsychological Outcomes in HIV/HCV Co-infection
|
HEAPS, JODI
|
UNIVERSITY OF MISSOURI-ST. LOUIS
|
MO
|
$30,432
|
|
Hepatitis
|
2012
|
NIAID
|
5R01AI060389-11
|
|
The Host Response to Hepatitis C Virus
|
GALE, MICHAEL
|
UNIVERSITY OF WASHINGTON
|
WA
|
$374,928
|
|
Hepatitis
|
2012
|
NIAID
|
5R01AI076558-04
|
|
Orally Active Nucleoside Phosphonates for Hepatitis C Virus
|
SCHOOLEY, ROBERT
|
UNIVERSITY OF CALIFORNIA AT SAN DIEGO
|
CA
|
$545,533
|
|
Hepatitis
|
2012
|
NIDDK
|
5R01DK080711-05
|
|
Hepatitis C Virus Quasispecies in the Resistance to Antiviral Therapy
|
FAN, XIAOFENG
|
SAINT LOUIS UNIVERSITY
|
MO
|
$288,149
|
|
Hepatitis
|
2012
|
NIDA
|
5K01DA024654-05
|
|
Antiviral Role of APOBEC3 in HIV/HCV Coinfected Patients
|
PILLAI, SATISH
|
UNIV OF CALIFORNIA AT SAN FRANCISCO
|
CA
|
$180,074
|
|
Hepatitis
|
2012
|
NIAID
|
5R01AI094409-02
|
|
Antisense Mediated Treatment of Hepatitis B Virus Infection
|
WIELAND, STEFAN
|
SCRIPPS RESEARCH INSTITUTE
|
CA
|
$768,305
|
|
Hepatitis
|
2012
|
NIGMS
|
5R01GM083257-04
|
|
Small Molecule Tools to Image Sophisticated Protein Function
|
SCHEPARTZ, ALANNA
|
YALE UNIVERSITY
|
CT
|
$312,470
|
|
Hepatitis
|
2012
|
NCI
|
1R03CA165122-01
|
|
Lipogenic inhibitors in prevention of oncogene induced liver cancer
|
CHEN, XIN
|
UNIV OF CALIFORNIA AT SAN FRANCISCO
|
CA
|
$77,250
|
|
Hepatitis
|
2012
|
NIDA
|
5R01DA016147-09
|
|
HBV Prevention for Homeless at Risk for HBV/HCV/HIV
|
NYAMATHI, ADELINE
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
CA
|
$599,827
|
|
Hepatitis
|
2012
|
NCI
|
5R01CA127481-05
|
|
Hepatocarcinogenesis Secondary to Hepatitis C
|
DASH, SRIKANTA
|
TULANE UNIVERSITY OF LOUISIANA
|
LA
|
$272,731
|
|
Hepatitis
|
2012
|
NIGMS
|
5R37GM056207-16
|
|
Simulation of Proton and Hydride Transfer in Enzymes
|
HAMMES-SCHIFFER, SHARON
|
PENNSYLVANIA STATE UNIVERSITY-UNIV PARK
|
PA
|
$72,539
|
|
Hepatitis
|
2012
|
NIDA
|
5R01DA011602-14
|
|
HIV Disease Outcomes in Drug Users in Clinical Practice
|
MOORE, RICHARD
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$683,258
|
|
Hepatitis
|
2012
|
NIAAA
|
5R01AA014428-08
|
|
Homocysteine, ER Stress and Alcoholic Liver Injury.
|
KAPLOWITZ, NEIL
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
CA
|
$369,822
|
|
Hepatitis
|
2012
|
NIDDK
|
5K01DK087776-03
|
|
Regulation of lipid metabolism by macroautophagy
|
SINGH, RAJAT
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
NY
|
$136,961
|
|
Hepatitis
|
2012
|
NIAID
|
1R21AI094639-01A1
|
|
Prodrug Strategies for HCV Nucleoside Lead Development
|
RADTKE, KATHERINE
|
UNIVERSITY OF MARYLAND BALT CO CAMPUS
|
MD
|
$194,122
|
|
Hepatitis
|
2012
|
NHLBI
|
5R01HL105704-02
|
|
Broad Detection of Infectious Agents in Blood by Microarrays and Deep Sequencing
|
CHIU, CHARLES
|
UNIV OF CALIFORNIA AT SAN FRANCISCO
|
CA
|
$582,335
|
|
Hepatitis
|
2012
|
NIDDK
|
5R01DK083356-03
|
|
Defining the intrahepatic immune response to hepatitis C virus
|
GRAKOUI, ARASH
|
EMORY UNIVERSITY
|
GA
|
$359,206
|
|
Hepatitis
|
2012
|
NCI
|
1R43CA165293-01
|
|
Prime/Boost Vaccine to Prevent Hepatocellular Carcinoma
|
ELDRIDGE, JOHN
|
PROFECTUS BIOSCIENCES, INC.
|
MD
|
$300,000
|
|
Hepatitis
|
2012
|
NCI
|
1R43CA165312-01
|
|
Development of a Urine Test for the Early Detection of Liver Cancer
|
SONG, WEI
|
JBS SCIENCE, INC.
|
PA
|
$247,245
|
|
Hepatitis
|
2012
|
NIAID
|
2R44AI084307-02
|
|
Integrated software application for management of Hepatitis C Virus data
|
CRAIG, JOHANNA
|
GATACA, LLC
|
VA
|
$692,375
|
|
Hepatitis
|
2012
|
NIDDK
|
5R01DK090794-02
|
|
Heat Shock Protein Synthesis Inhibitor Treatment of Hepatitis C Viral Infection
|
FRENCH, SAMUEL
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
CA
|
$334,950
|
|
Hepatitis
|
2012
|
NIAID
|
1F33AI098354-01
|
|
Backbone Modified Peptide-nucleic Acids as Antiviral Agents Against Hepatitis C
|
MIHAILESCU, MIHAELA
|
CARNEGIE-MELLON UNIVERSITY
|
PA
|
$62,030
|
|
Hepatitis
|
2012
|
NCI
|
5R01CA138635-03
|
|
Multiple Tumor Antigen-loaded DC Vaccine for Hepatocellular Cancer
|
BUTTERFIELD, LISA
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$407,715
|
|
Hepatitis
|
2012
|
NIDDK
|
5F30DK088385-03
|
|
The Molecular Mechanism of Antibody Neutralization of Hepatitis C Virus
|
SABO, MICHELLE
|
WASHINGTON UNIVERSITY
|
MO
|
$47,232
|
|
Hepatitis
|
2012
|
NIAID
|
5R01AI095690-02
|
|
Micro-RNA 122 and Chronic Hepatitis C
|
LEMON, STANLEY
|
UNIVERSITY OF N CAROLINA AT CHAPEL HILL
|
NC
|
$368,389
|
|
Hepatitis
|
2012
|
NIDA
|
5K23DA027367-03
|
|
HCV and Pain in Substance Users With and Without HIV
|
TSUI, JUDITH
|
BOSTON MEDICAL CENTER
|
MA
|
$167,211
|
|
Hepatitis
|
2012
|
NIAID
|
5R01AI080703-03
|
|
Hepatitis C Virus Trafficking in Infected Hepatocytes
|
RANDALL, GLENN
|
UNIVERSITY OF CHICAGO
|
IL
|
$342,700
|
|
Hepatitis
|
2012
|
NIAID
|
5K23AI066983-05
|
|
HIV and Hepatitis B Coinfection: Hepatitis B Genotype, Resistance and Outcomes
|
BHATTACHARYA, DEBIKA
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
CA
|
$123,390
|
|
Hepatitis
|
2012
|
NIAID
|
5R01AI085051-03
|
|
Drug Resistance in HCV NS3/4A - Inhibitor binding versus substrate recognition
|
SCHIFFER, CELIA
|
UNIV OF MASSACHUSETTS MED SCH WORCESTER
|
MA
|
$407,138
|
|
Hepatitis
|
2012
|
NIDA
|
5R01DA015999-08
|
|
Treatment of recently acquired hepatitis C virus infection
|
DORE, GREGORY
|
UNIVERSITY OF NEW SOUTH WALES
|
AUSTRA
|
$363,999
|
|
Hepatitis
|
2012
|
NIDDK
|
5K23DK082621-04
|
|
Concentration-Controlled Ribavirin for the Treatment of Patients with Chronic HVC
|
KISER, JENNIFER
|
UNIVERSITY OF COLORADO DENVER
|
CO
|
$167,815
|
|
Hepatitis
|
2012
|
NIAID
|
5R01AI094469-02
|
|
Preclinical Development of SB 44 as an Orally Bioavailable Anti-HBV Agent
|
IYER, RADHAKRISHNAN
|
SPRING BANK TECHNOLOGIES, INC.
|
MA
|
$590,928
|
|
Hepatitis
|
2012
|
NHLBI
|
1R21HL112658-01
|
|
Biomarkers of spontaneous acute hepatitis C virus resolution
|
SELVARAJAH, SUGANYA
|
BLOOD SYSTEMS RESEARCH INSTITUTE
|
CA
|
$118,500
|
|
Hepatitis
|
2012
|
NIAID
|
5R42AI088793-04
|
|
Advancing clemizole for hepatitis C: towards a pre-IND package--Phase II
|
MURPHY, BRIAN
|
EIGER GROUP INTERNATIONAL, INC.
|
CA
|
$1,000,000
|
|
Hepatitis
|
2012
|
NIAID
|
5R01AI094474-02
|
|
Development of a novel drug candidate that inhibits hepatitis B virus covalently
|
GUO, HAITAO
|
DREXEL UNIVERSITY
|
PA
|
$627,419
|
|
Hepatitis
|
2012
|
NIDA
|
5R01DA016017-10
|
|
Acute Hepatitis C Infection in Young Injectors
|
PAGE, KIMBERLY
|
UNIV OF CALIFORNIA AT SAN FRANCISCO
|
CA
|
$1,027,825
|
|
Hepatitis
|
2012
|
NIDA
|
5R37DA013806-13
|
|
HIV HCV Coinfection Antiviral Therapy and Fibrosis
|
THOMAS, DAVID
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$646,848
|
|
Hepatitis
|
2012
|
NIDA
|
5R01DA021550-05
|
|
HCV Transmission among Young IDUs in NYC
|
EDLIN, BRIAN
|
SUNY DOWNSTATE MEDICAL CENTER
|
NY
|
$772,124
|
|
Hepatitis
|
2012
|
NIDA
|
1R43DA033158-01
|
|
Treatment of HCV infection by microRNA clusters in HCV/HIV co-infected drug users
|
THIBONNIER, MARC
|
AMERICAN GENE TECHNOLOGIES INTERNATIONAL
|
MD
|
$181,796
|
|
Hepatitis
|
2012
|
NIDDK
|
5K24DK066144-08
|
|
Mentoring Junior Faculty: Viral hepatitis Clinical Research
|
FRIED, MICHAEL
|
UNIVERSITY OF N CAROLINA AT CHAPEL HILL
|
NC
|
$153,330
|
|
Hepatitis
|
2012
|
NIDA
|
1R01DA031059-01A1
|
|
Simulation Modeling to Improve HIV/HCV Screening, Treatment and Care
|
LINAS, BENJAMIN
|
BOSTON MEDICAL CENTER
|
MA
|
$436,800
|
|
Hepatitis
|
2012
|
NIAID
|
1R01AI095097-01A1
|
|
HIV co-infection and HCV-induced liver fibrosis in vivo
|
SU, LISHAN
|
UNIVERSITY OF N CAROLINA AT CHAPEL HILL
|
NC
|
$370,000
|
|
Hepatitis
|
2012
|
NIDA
|
5R13DA022952-06
|
|
International Society for Addiction Medicine Annual Conference
|
BUNT, GREGORY
|
DAYTOP VILLAGE
|
NY
|
$40,000
|
|
Hepatitis
|
2012
|
NIDA
|
1K23DA031612-01A1
|
|
Supporting Health in Drug Treatment Court for Women with HIV or Hepatitis C
|
MORSE, DIANE
|
UNIVERSITY OF ROCHESTER
|
NY
|
$172,099
|
|
Hepatitis
|
2012
|
NIAID
|
5R01AI067417-08
|
|
Molecular Modulation of Virus Capsid Assembly
|
ZLOTNICK, ADAM
|
INDIANA UNIVERSITY BLOOMINGTON
|
IN
|
$480,376
|
|
Hepatitis
|
2012
|
NIDA
|
5R01DA031056-02
|
|
International Collaborative of prospective studies of HIV and Hepatitis in IDU
|
PAGE, KIMBERLY
|
UNIV OF CALIFORNIA AT SAN FRANCISCO
|
CA
|
$438,391
|
|
Hepatitis
|
2012
|
NIMH
|
5R01MH092225-03
|
|
Clinical Trial of CNS Penetrating ART to Prevent NeuroAIDS in China
|
LETENDRE, SCOTT
|
UNIVERSITY OF CALIFORNIA AT SAN DIEGO
|
CA
|
$524,494
|
|
Hepatitis
|
2012
|
NINR
|
1R21NR013461-01
|
|
Patient self-management and gene guided therapy for CHC
|
BAILEY, DONALD
|
DUKE UNIVERSITY
|
NC
|
$235,500
|
|
Hepatitis
|
2012
|
NIAID
|
5R21AI096958-02
|
|
Occult Hepatitis B Infection in South African HIV Patients
|
BLACKARD, JASON
|
UNIVERSITY OF CINCINNATI
|
OH
|
$190,194
|
|
Hepatitis
|
2012
|
NIDA
|
5R01DA027213-04
|
|
Health Promotion Coaching/Vaccine for Homeless Parolees
|
NYAMATHI, ADELINE
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
CA
|
$625,189
|
|
Hepatitis
|
2012
|
NIDA
|
5R01DA022914-05
|
|
Couples-Based HIV/STI Prevention for Injecting Drug Users in Kazakhstan
|
EL-BASSEL, NABILA
|
COLUMBIA UNIV NEW YORK MORNINGSIDE
|
NY
|
$609,760
|
|
Hepatitis
|
2012
|
NIEHS
|
1R01ES021375-01
|
|
PCBs worsen obesity/metabolic syndrome through 'toxic metabolic endotoxemia'
|
CAVE, MATTHEW
|
UNIVERSITY OF LOUISVILLE
|
KY
|
$337,125
|
|
Hepatitis
|
2012
|
NCI
|
5R01CA153073-03
|
|
The Effect of Aflatoxin Regulation on Global Liver Cancer Risk
|
WU, FELICIA
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$233,071
|
|
Hepatitis
|
2012
|
NIAID
|
5R01AI078881-02
|
|
Collaborative Integration of HCV Molecular Virology and Mathematical Modeling
|
UPRICHARD, SUSAN
|
UNIVERSITY OF ILLINOIS
|
IL
|
$138,054
|
|
Hepatitis
|
2012
|
NCI
|
5K07CA132955-03
|
|
HBV reactivation among cancer patients receiving chemotherapy
|
HWANG, JESSICA
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
TX
|
$140,399
|
|
Hepatitis
|
2012
|
NIAAA
|
5R44AA016712-04
|
|
Novel Catalytic MetalloDrug Targeting IRES RNA for Treatment of HCV Infection
|
COWAN, ADA
|
METALLOPHARM, LLC
|
OH
|
$813,038
|
|
Hepatitis
|
2012
|
NIAAA
|
5R37AA009300-17
|
|
Lipid Aldehyde and Ethanol Induced Liver Damage
|
PETERSEN, DENNIS
|
UNIVERSITY OF COLORADO DENVER
|
CO
|
$410,782
|
|
Hepatitis
|
2012
|
NCI
|
1R01CA166213-01
|
|
Super-infection and virus spread during chronic hepadnaviral infection
|
GUDIMA, SEVERIN
|
UNIVERSITY OF KANSAS MEDICAL CENTER
|
KS
|
$339,534
|
|
Hepatitis
|
2012
|
NIAID
|
1R15AI099134-01
|
|
3C Protease Polyubiquitylation as a Picornavirus Replication Success Determinant
|
LAWSON, THOMAS
|
BATES COLLEGE
|
ME
|
$350,000
|
|
Hepatitis
|
2012
|
NCI
|
7R01CA138698-03
|
|
Epidemiologic Study of Hepatocellular Carcinoma in the US
|
YU, HERBERT
|
UNIVERSITY OF HAWAII AT MANOA
|
HI
|
$1,059,509
|
|
Hepatitis
|
2012
|
NIDDK
|
5R01DK053792-11
|
|
Liver Disease in Obesity
|
DIEHL, ANNA MAE
|
DUKE UNIVERSITY
|
NC
|
$320,463
|
|
Hepatitis
|
2012
|
NIDDK
|
5R01DK065122-09
|
|
Role of SH2-B in Glucose Metabolism
|
RUI, LIANGYOU
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
MI
|
$351,718
|
|
Hepatitis
|
2012
|
NIAID
|
5R01AI077688-04
|
|
The Biophysics of Virus Capsid Assembly
|
ZLOTNICK, ADAM
|
INDIANA UNIVERSITY BLOOMINGTON
|
IN
|
$291,616
|
|
Hepatitis
|
2012
|
NIAID
|
5R01AI081987-03
|
|
Investigating the Catalytic Mechanism of the HDV Ribozyme
|
PICCIRILLI, JOSEPH
|
UNIVERSITY OF CHICAGO
|
IL
|
$375,456
|
|
Hepatitis
|
2012
|
NIAID
|
5R01AI056289-11
|
|
Recombinant Attenuated Salmonella Vaccines for Humans
|
CURTISS, ROY
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
AZ
|
$373,663
|
|
Hepatitis
|
2012
|
NINDS
|
1R21NS078238-01
|
|
A novel neuroprotective strategy
|
AIZENMAN, ELIAS
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$220,369
|
|
Hepatitis
|
2012
|
NIDA
|
5R01DA027195-02
|
|
Reducing HCV/HIV Risk Behaviors among Injection Drug Users in China
|
DU, JIANG
|
SHANGHAI MENTAL HEALTH CENTER
|
CHINA
|
$77,936
|
|
Hepatitis
|
2012
|
NIAID
|
5R01DA030747-03
|
|
CARE Corrections: Technology for Jail HIV/HCV Testing, Linkage, and Care (TLC)
|
BECKWITH, CURT
|
MIRIAM HOSPITAL
|
RI
|
$282,355
|
|
Hepatitis
|
2012
|
NIDA
|
5R01DA030747-03
|
|
CARE Corrections: Technology for Jail HIV/HCV Testing, Linkage, and Care (TLC)
|
BECKWITH, CURT
|
MIRIAM HOSPITAL
|
RI
|
$998,788
|
|
Hepatitis
|
2012
|
NIAID
|
5R01AI079043-03
|
|
Innate Control of Hepatitis C Virus Infection: Antiviral and Evasion Mechanisms
|
CHISARI, FRANCIS
|
SCRIPPS RESEARCH INSTITUTE
|
CA
|
$470,003
|
|
Hepatitis
|
2012
|
NIAID
|
5R01AI076535-05
|
|
Combination therapies for chronic HBV, liver disease and cancer
|
FEITELSON, MARK
|
TEMPLE UNIVERSITY
|
PA
|
$347,054
|
|
Hepatitis
|
2012
|
NINR
|
1R21NR013538-01
|
|
Enhancing Psychological Capital to Foster Health Outcomes in Homeless Young Women
|
REW, DONNA
|
UNIVERSITY OF TEXAS AUSTIN
|
TX
|
$222,418
|
|
Hepatitis
|
2012
|
NIDDK
|
1K01DK095031-01
|
|
Interactions between type I and III interferon during resolution of HCV infection
|
SCHOGGINS, JOHN
|
ROCKEFELLER UNIVERSITY
|
NY
|
$130,591
|
|
Hepatitis
|
2012
|
NIAID
|
5R01AI091953-02
|
|
Viral and Cellular Determinants of HCV Assembly
|
LUO, GUANGXIANG
|
UNIVERSITY OF KENTUCKY
|
KY
|
$371,250
|
|
Hepatitis
|
2012
|
NIDA
|
5K23DA020383-05
|
|
Buprenorphine as a Bridge to HCV Treatment for HIV/HCV Coinfected Opioid Users
|
TAYLOR, LYNN
|
MIRIAM HOSPITAL
|
RI
|
$175,268
|
|
Hepatitis
|
2012
|
NIAID
|
1R01AI099284-01
|
|
Hepatitis C antivirals: Mechanism of action, combination efficacy and resistance
|
RICE, CHARLES
|
ROCKEFELLER UNIVERSITY
|
NY
|
$735,361
|
|
Hepatitis
|
2012
|
NIAID
|
1R01AI099245-01
|
|
The PIP2-virus interface and PI 4-kinase: novel biology and validation targets
|
GLENN, JEFFREY
|
STANFORD UNIVERSITY
|
CA
|
$1,127,800
|
|
Hepatitis
|
2012
|
NIDA
|
5K23DA023467-05
|
|
Chronic Pain and Substance Use in Patients with Hepatitis C
|
MORASCO, BENJAMIN
|
OREGON HEALTH AND SCIENCE UNIVERSITY
|
OR
|
$166,684
|
|
Hepatitis
|
2012
|
NIAID
|
5R01AI090119-03
|
|
Regulated Intramembrane Proteolysis of CREB3L1 in Innate Antiviral Response
|
YE, JIN
|
UNIV OF TX SW MED CTR-DALLAS
|
TX
|
$393,422
|
|
Hepatitis
|
2012
|
NIDA
|
5R01DA025932-05
|
|
Drug Interactions in Substance Abusers with HIV Infection
|
FRIEDLAND, GERALD
|
YALE UNIVERSITY
|
CT
|
$357,593
|
|
Hepatitis
|
2012
|
NIAID
|
5R01AI085087-03
|
|
Role of Lipids in Hepatitis C Virus Maturation
|
SIDDIQUI, ALEEM
|
UNIVERSITY OF CALIFORNIA AT SAN DIEGO
|
CA
|
$382,388
|
|
Hepatitis
|
2012
|
NIAID
|
5R01AI076259-04
|
|
Molecular determinants of hepatitis C virus infectivity
|
LINDENBACH, BRETT
|
YALE UNIVERSITY
|
CT
|
$405,516
|
|
Hepatitis
|
2012
|
NIAID
|
5R01AI089826-03
|
|
Structure and function of the HCV replication complex
|
PYLE, ANNA
|
YALE UNIVERSITY
|
CT
|
$591,666
|
|
Hepatitis
|
2012
|
NIAID
|
5K24AI078884-05
|
|
Complications of Chronic Viral Infections
|
GLESBY, MARSHALL
|
WEILL MEDICAL COLLEGE OF CORNELL UNIV
|
NY
|
$183,986
|
|
Hepatitis
|
2012
|
NIMH
|
5R01MH083553-05
|
|
Neurobehavioral Deficits in HIV/HCV Infection Pre/Post Anti-HCV Therapy
|
HINKIN, CHARLES
|
BRENTWOOD BIOMEDICAL RESEARCH INSTITUTE
|
CA
|
$564,172
|
|
Hepatitis
|
2012
|
NIDA
|
5R01DA029880-03
|
|
HIV and Drug Use in Georgian Women
|
JONES, HENDREE
|
RESEARCH TRIANGLE INSTITUTE
|
NC
|
$433,226
|
|
Hepatitis
|
2012
|
NIAID
|
5R01AI071068-07
|
|
RNAi for the Treatment of Viral Hepatitis
|
KAY, MARK
|
STANFORD UNIVERSITY
|
CA
|
$453,663
|
|
Hepatitis
|
2012
|
NIDDK
|
5R01DK088375-04
|
|
Accurate Measurement of Renal Function in Cirrhosis
|
LEE, VIVIAN
|
UNIVERSITY OF UTAH
|
UT
|
$514,948
|
|
Hepatitis
|
2012
|
NIMHD
|
5R01MD005819-03
|
|
Prevention of hepatocellular carcinoma in vulnerable communities in Texas
|
PHILLIPS, TIMOTHY
|
TEXAS A&M UNIVERSITY SYSTEM
|
TX
|
$329,746
|
|
Hepatitis
|
2012
|
NIDDK
|
5R01DK081410-04
|
|
Molecular Determinants of Disease Progression in Nonalcoholic Steatohepatitis
|
SANYAL, ARUN
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
VA
|
$318,692
|
|
Hepatitis
|
2012
|
NIDDK
|
5R01DK082451-05
|
|
Caspase Dependent Cell Death in Nonalcoholic Fatty Liver Disease
|
FELDSTEIN, ARIEL
|
UNIVERSITY OF CALIFORNIA AT SAN DIEGO
|
CA
|
$330,417
|
|
Hepatitis
|
2012
|
NIDA
|
5R01DA016065-10
|
|
HCV Disease Management in HIV- HCV Coinfected IDUs
|
SULKOWSKI, MARK
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$408,118
|
|
Hepatitis
|
2012
|
NIDA
|
5K23DA022454-05
|
|
Directly Observed Hepatitis C Treatment in Methadone Clinics
|
LITWIN, ALAIN
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
NY
|
$179,611
|
|
Hepatitis
|
2012
|
NIDA
|
5R01DA030234-03
|
|
Behavioral Science Aspects of Rapid Test Acceptance
|
FISHER, DENNIS
|
CALIFORNIA STATE UNIVERSITY LONG BEACH
|
CA
|
$502,733
|
|
Hepatitis
|
2012
|
NIAID
|
5R01AI087176-03
|
|
Visceral Adiposity, HIV, and HCV: Biologic Mediators of Hepatic Steatosis
|
TIEN, PHYLLIS
|
NORTHERN CALIFORNIA INSTITUTE RES & EDUC
|
CA
|
$617,477
|
|
Hepatitis
|
2012
|
NIAID
|
5R01AI076357-05
|
|
A Murine Model of Chronic Autoimmune Hepatitis and Liver Fibrosis
|
ZHONG, XIAOPING
|
DUKE UNIVERSITY
|
NC
|
$305,791
|
|
Hepatitis
|
2012
|
NCI
|
1P30AI094189-01A1
|
5955
|
Clinical
|
MOORE, RICHARD
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$60,747
|
|
Hepatitis
|
2012
|
NHLBI
|
1P30AI094189-01A1
|
5955
|
Clinical
|
MOORE, RICHARD
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$50,483
|
|
Hepatitis
|
2012
|
NIA
|
1P30AI094189-01A1
|
5955
|
Clinical
|
MOORE, RICHARD
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$4,946
|
|
Hepatitis
|
2012
|
NIAID
|
1P30AI094189-01A1
|
5955
|
Clinical
|
MOORE, RICHARD
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$248,001
|
|
Hepatitis
|
2012
|
NICHD
|
1P30AI094189-01A1
|
5955
|
Clinical
|
MOORE, RICHARD
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$22,981
|
|
Hepatitis
|
2012
|
NIDA
|
1P30AI094189-01A1
|
5955
|
Clinical
|
MOORE, RICHARD
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$37,932
|
|
Hepatitis
|
2012
|
NIMH
|
1P30AI094189-01A1
|
5955
|
Clinical
|
MOORE, RICHARD
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$41,478
|
|
Hepatitis
|
2012
|
OD
|
8R01OD011095-21
|
|
Modeling Viral and T Lymphocyte Dynamics
|
PERELSON, ALAN
|
LOS ALAMOS NAT SECTY-LOS ALAMOS NAT LAB
|
NM
|
$476,303
|
|
Hepatitis
|
2012
|
NIAID
|
5K23AI096913-02
|
|
Moving Towards More Individualized Therapies in HIV/HCV Co-infected Patients
|
NAGGIE, SUSANNA
|
DUKE UNIVERSITY
|
NC
|
$88,700
|
|
Hepatitis
|
2012
|
NIDDK
|
5R01DK083380-03
|
|
Technical Development of Quantitative Biomarkers of Fatty Liver Disease with MRI
|
REEDER, SCOTT
|
UNIVERSITY OF WISCONSIN MADISON
|
WI
|
$298,680
|
|
Hepatitis
|
2012
|
NIDDK
|
5K08DK085432-03
|
|
Drug Induced Hepatotoxicity During Viral Hepatitis
|
GETACHEW, YONAS
|
UNIV OF TX SW MED CTR-DALLAS
|
TX
|
$142,668
|
|
Hepatitis
|
2012
|
NIDDK
|
5K08DK088951-03
|
|
The Relationship of Host Cholesterol Biosynthesis to Chronic HCV Infection
|
PENG, LEE
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$158,949
|
|
Hepatitis
|
2012
|
NIAID
|
5R01AI083113-03
|
|
HCV resolution correlates with patterned KIR expressions on lymphocytes.
|
RYAN, JAMES
|
UNIV OF CALIFORNIA AT SAN FRANCISCO
|
CA
|
$402,932
|
|
Hepatitis
|
2012
|
NCI
|
1R01CA161694-01A1
|
|
Aflatoxin B1 hepatocarcinogenesis in the mGSTA3-/- mouse
|
SELL, STEWART
|
WADSWORTH CENTER
|
NY
|
$292,725
|
|
Hepatitis
|
2012
|
NIAID
|
1R01AI097242-01A1
|
|
Development of High Throughput Assays for the Hepatitis C Virus NS2 Protease
|
TELLINGHUISEN, TIMOTHY
|
SCRIPPS FLORIDA
|
FL
|
$346,500
|
|
Hepatitis
|
2012
|
NIAID
|
2R01AI070101-06A1
|
|
Mechanisms of hepatitis C virus persistence
|
GRAKOUI, ARASH
|
EMORY UNIVERSITY
|
GA
|
$146,666
|
|
Hepatitis
|
2012
|
NICHD
|
5R01HD040787-13
|
|
Study to Investigate the Pathophysiology of Type 2 Diabetes in Youth
|
CAPRIO, SONIA
|
YALE UNIVERSITY
|
CT
|
$366,010
|
|
Hepatitis
|
2012
|
NIAID
|
5R01AI076318-04
|
|
Inferring in vivo Capsid Assembly Kinetics from in vitro by Stochastic Simulation
|
SCHWARTZ, RUSSELL
|
CARNEGIE-MELLON UNIVERSITY
|
PA
|
$285,412
|
|
Hepatitis
|
2012
|
NIAID
|
5K08AI083785-03
|
|
Characterization of a host hepatocyte factor that regulates HCV replication
|
TAI, ANDREW
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
MI
|
$132,300
|
|
Hepatitis
|
2012
|
NIDDK
|
5K23DK080888-05
|
|
Biological Determinants of Steatohepatitis after Adolescent Bariatric Surgery
|
XANTHAKOS, STAVRA
|
CHILDREN'S HOSPITAL MEDICAL CENTER CINCI
|
OH
|
$176,234
|
|
Hepatitis
|
2012
|
NIAAA
|
2R01AA012863-12
|
|
Mechanisms of Liver Injury by Hepatitis C and Alcohol
|
WEINMAN, STEVEN
|
UNIVERSITY OF KANSAS MEDICAL CENTER
|
KS
|
$516,577
|
|
Hepatitis
|
2012
|
NIAID
|
5R01AI095680-02
|
|
The Innate Immune Response in the Marmoset Model of GBV-B Infections: A Surrogate
|
LANFORD, ROBERT
|
TEXAS BIOMEDICAL RESEARCH INSTITUTE
|
TX
|
$552,679
|
|
Hepatitis
|
2012
|
NIDDK
|
5K01DK082613-04
|
|
Host-pathogen interactions in hepatitis C virus replication
|
BRADRICK, SHELTON
|
DUKE UNIVERSITY
|
NC
|
$110,664
|
|
Hepatitis
|
2012
|
NIAID
|
5F32AI091207-03
|
|
Characterization and Consequences of HCV Interaction with Host Lipoproteins
|
SCULL, MARGARET
|
ROCKEFELLER UNIVERSITY
|
NY
|
$52,190
|
|
Hepatitis
|
2012
|
NIDDK
|
5R01DK068450-07
|
|
Dietary Factors in the Pathogenesis of Steatohepatitis
|
MAHER, JACQUELYN
|
UNIV OF CALIFORNIA AT SAN FRANCISCO
|
CA
|
$394,639
|
|
Hepatitis
|
2012
|
NIDDK
|
5R01DK080812-04
|
|
Mechanisms of Liver Disease Progression by Hepatitis C Virus
|
RAY, RANJIT
|
SAINT LOUIS UNIVERSITY
|
MO
|
$314,429
|
|
Hepatitis
|
2012
|
NIDDK
|
5R01DK081817-04
|
|
Innate Immunity and Hepatitis C Virus Infection
|
RAY, RATNA
|
SAINT LOUIS UNIVERSITY
|
MO
|
$314,429
|
|
Hepatitis
|
2012
|
NIDDK
|
2K24DK078154-06
|
|
Epidemiology and Outcomes of Digestive and Liver Diseases: A Mentoring Program
|
EL-SERAG, HASHEM
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$98,954
|
|
Hepatitis
|
2012
|
NIDDK
|
2K24DK078772-06
|
|
Patient-Oriented Research on Hepatitis in Special Populations
|
CHUNG, RAYMOND
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$160,354
|
|
Hepatitis
|
2012
|
NIAAA
|
1R21AA020587-01A1
|
|
ROLE OF WNT SIGNALING IN CHRONIC ALCOHOLIC LIVER DISEASE
|
KIM, MIRAN
|
RHODE ISLAND HOSPITAL
|
RI
|
$228,563
|
|
Hepatitis
|
2012
|
NIDDK
|
1K23DK090209-01A1
|
|
Gender and hormonal influences on liver fibrosis after transplant for hepatitis C
|
FORDE, KIMBERLY
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$182,110
|
|
Hepatitis
|
2012
|
NCI
|
5U01AI069919-07
|
|
IeDEA West -Africa collaboration
|
DABIS, FRANCOIS
|
ADERA
|
FR
|
$308,922
|
|
Hepatitis
|
2012
|
NIAID
|
5U01AI069919-07
|
|
IeDEA West -Africa collaboration
|
DABIS, FRANCOIS
|
ADERA
|
FR
|
$1,887,309
|
|
Hepatitis
|
2012
|
NICHD
|
5U01AI069919-07
|
|
IeDEA West -Africa collaboration
|
DABIS, FRANCOIS
|
ADERA
|
FR
|
$300,000
|
|
Hepatitis
|
2012
|
NIGMS
|
5R01GM071940-08
|
|
High-Resolution CryoEM Reconstruction of Large Complexes
|
ZHOU, Z
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
CA
|
$289,608
|
|
Hepatitis
|
2012
|
NIDDK
|
5K08DK083774-03
|
|
Thioredoxin Inhibitory Protein in Chronic Liver Disease
|
HAMILTON, JAMES
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$155,785
|
|
Hepatitis
|
2012
|
NIDA
|
5R01DA027689-03
|
|
Exploratory Research on Late Initiation of Drug Injection
|
BLUTHENTHAL, RICKY
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
CA
|
$513,017
|
|
Hepatitis
|
2012
|
NIDDK
|
5U01DK061713-11
|
|
NASH Clinical Research Network
|
DIEHL, ANNA MAE
|
DUKE UNIVERSITY
|
NC
|
$511,429
|
|
Hepatitis
|
2012
|
NIDDK
|
5U01DK061718-11
|
|
The Saint Louis University Component of the NASH Clinical Research Network
|
NEUSCHWANDER-TETRI, BRENT
|
SAINT LOUIS UNIVERSITY
|
MO
|
$494,413
|
|
Hepatitis
|
2012
|
NIDDK
|
5U01DK061728-12
|
|
Clinical Research Network in Non-Alcoholic Steatohepatitis
|
KOWDLEY, KRIS
|
BENAROYA RESEARCH INST AT VIRGINIA MASON
|
WA
|
$291,944
|
|
Hepatitis
|
2012
|
NIDDK
|
5U01DK061730-11
|
|
Continuation of the Non-Alcoholic Steatohepatitis Clinical Research Network
|
TONASCIA, JAMES
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$1,301,584
|
|
Hepatitis
|
2012
|
NIDDK
|
5U01DK061731-11
|
|
Nonalcoholic Steatohepatitis Clinical Research Network
|
SANYAL, ARUN
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
VA
|
$633,846
|
|
Hepatitis
|
2012
|
NIDDK
|
5U01DK061732-11
|
|
Clincal Research Network in Non-Alcoholic Steatohepatitis (NASH CRN)
|
MCCULLOUGH, ARTHUR
|
THE CLEVELAND CLINC FOUNDATION
|
OH
|
$454,799
|
|
Hepatitis
|
2012
|
NICHD
|
5U01DK061734-11
|
|
Clinical Research on Nonalcoholic Fatty Liver Disease
|
LAVINE, JOEL
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
NY
|
$487,575
|
|
Hepatitis
|
2012
|
NIDDK
|
5U01DK061734-11
|
|
Clinical Research on Nonalcoholic Fatty Liver Disease
|
LAVINE, JOEL
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
NY
|
$681,069
|
|
Hepatitis
|
2012
|
NIDDK
|
5U01DK061737-11
|
|
Collaborative Clinical Research on Non Alcoholic Stratohepatitis
|
CHALASANI, NAGA
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
IN
|
$628,215
|
|
Hepatitis
|
2012
|
NIDDK
|
5U01DK061738-11
|
|
Continuation of the Nonalcoholic Steatohepatitis Clinical Research Network
|
TERRAULT, NORAH
|
UNIV OF CALIFORNIA AT SAN FRANCISCO
|
CA
|
$430,461
|
|
Hepatitis
|
2012
|
NIDDK
|
1R01DK093526-01A1
|
|
Tim-3-mediated IL-12 dysregulation in antiviral responses to HCV infection
|
YAO, ZHI
|
EAST TENNESSEE STATE UNIVERSITY
|
TN
|
$317,550
|
|
Hepatitis
|
2012
|
NHLBI
|
1R34HL109334-01A1
|
|
Viral kinetic models of HCV clearance in hemophiliacs treated with telaprevir
|
SHERMAN, KENNETH
|
UNIVERSITY OF CINCINNATI
|
OH
|
$372,151
|
|
Hepatitis
|
2012
|
NIAID
|
2R01AI052447-10
|
|
Gene Silencing as an Antiviral Defense in Animal Cells
|
DING, SHOU-WEI
|
UNIVERSITY OF CALIFORNIA RIVERSIDE
|
CA
|
$369,889
|
|
Hepatitis
|
2012
|
NCI
|
2R01CA114102-06A1
|
|
The RB pathway in liver cancer
|
SAGE, JULIEN
|
STANFORD UNIVERSITY
|
CA
|
$277,418
|
|
Hepatitis
|
2012
|
NIAID
|
5R01AI077757-04
|
|
Mechanisms of Immune Evasion by Hepatitis C Virus
|
COX, ANDREA
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$401,841
|
|
Hepatitis
|
2012
|
NIAID
|
5R44AI081335-04
|
|
Agonists of the RIG-I Innate Immune Pathway
|
IADONATO, SHAWN
|
KINETA, INC.
|
WA
|
$956,404
|
|
Hepatitis
|
2012
|
NIDDK
|
5R42DK082087-03
|
|
Automated quantification of lipid droplets in fatty liver tissue sections
|
MCDONOUGH, PATRICK
|
VALA SCIENCES, INC.
|
CA
|
$720,643
|
|
Hepatitis
|
2012
|
NIAAA
|
5R21AA020561-02
|
|
Alcohol Intake and Hepatic Fat Metabolism
|
HUANG, LI SHIN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
NY
|
$190,000
|
|
Hepatitis
|
2012
|
NIDA
|
5R01DA031074-02
|
|
Drug tourism to Mexico: Impact of Mexicos new drug law on HIV-HCV-TB in US IDUs
|
GARFEIN, RICHARD
|
UNIVERSITY OF CALIFORNIA AT SAN DIEGO
|
CA
|
$606,420
|
|
Hepatitis
|
2012
|
NIDDK
|
5R01DK091601-02
|
|
Genetic determinants of NAFLD severity and progression
|
DISTEFANO, JOHANNA
|
TRANSLATIONAL GENOMICS RESEARCH INST
|
AZ
|
$634,699
|
|
Hepatitis
|
2012
|
NIAID
|
5K08AI079406-05
|
|
Novel antviral targets in Hepatitis C virus NS4B protein
|
EINAV, SHIRIT
|
STANFORD UNIVERSITY
|
CA
|
$130,599
|
|
Hepatitis
|
2012
|
NIDDK
|
5R01DK088940-02
|
|
Aerobic fitness, mitochondrial dysfunction, and fatty liver disease
|
THYFAULT, JOHN
|
UNIVERSITY OF MISSOURI-COLUMBIA
|
MO
|
$276,338
|
|
Hepatitis
|
2012
|
NIDDK
|
5R01DK090066-02
|
|
Role of PNPLA3 in Fatty Liver Disease
|
HOBBS, HELEN
|
UNIV OF TX SW MED CTR-DALLAS
|
TX
|
$365,604
|
|
Hepatitis
|
2012
|
NCI
|
1R01CA163805-01A1
|
|
Lay Health Worker Model to Reduce Liver Cancer Disparities in Asian Americans
|
JUON, HEE-SOON
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$617,848
|
|
Hepatitis
|
2012
|
NIAID
|
5R01AI090055-03
|
|
Simianizing hepatitis C: Defining the species-tropism of a hepatotropic virus
|
RICE, CHARLES
|
ROCKEFELLER UNIVERSITY
|
NY
|
$409,772
|
|
Hepatitis
|
2012
|
NCCAM
|
5R01AT006842-02
|
|
Mechanisms of Silymarin Hepatoprotection
|
POLYAK, STEPHEN
|
UNIVERSITY OF WASHINGTON
|
WA
|
$502,483
|
|
Hepatitis
|
2012
|
OD
|
5R01AT006842-02
|
|
Mechanisms of Silymarin Hepatoprotection
|
POLYAK, STEPHEN
|
UNIVERSITY OF WASHINGTON
|
WA
|
$50,308
|
|
Hepatitis
|
2012
|
NIAID
|
5R01AI079060-04
|
|
Immunological Priming to Hepatitis B Virus
|
ISOGAWA, MASANORI
|
SCRIPPS RESEARCH INSTITUTE
|
CA
|
$465,302
|
|
Hepatitis
|
2012
|
NIAID
|
5K24AI083742-04
|
|
Midcareer Investigator Award in Patient-Oriented Research (K24)
|
ROSEN, HUGO
|
UNIVERSITY OF COLORADO DENVER
|
CO
|
$191,392
|
|
Hepatitis
|
2012
|
NIDA
|
5R01DA029910-03
|
|
Prison Interventions and HIV Prevention Collaboration
|
ALTICE, FREDERICK
|
YALE UNIVERSITY
|
CT
|
$400,112
|
|
Hepatitis
|
2012
|
NIAAA
|
5R37AA010154-17
|
|
TNF Alpha and Recovery from Alchoholic Liver Injury
|
DIEHL, ANNA MAE
|
DUKE UNIVERSITY
|
NC
|
$365,257
|
|
Hepatitis
|
2012
|
NIDDK
|
5R01DK089185-03
|
|
Mechanisms and metabolic implications of LRP130 in NAFLD
|
COOPER, MARCUS
|
UNIV OF MASSACHUSETTS MED SCH WORCESTER
|
MA
|
$354,210
|
|
Hepatitis
|
2012
|
NIDDK
|
5R01DK082583-03
|
|
MLK3 in metabolic stress signaling
|
JAESCHKE, ANJA
|
UNIVERSITY OF CINCINNATI
|
OH
|
$322,517
|
|
Hepatitis
|
2012
|
NIAID
|
5R01AI080659-03
|
|
Mechanistic Studies of HCV E2
|
MARCOTRIGIANO, JOSEPH
|
RUTGERS THE ST UNIV OF NJ NEW BRUNSWICK
|
NJ
|
$383,625
|
|
Hepatitis
|
2012
|
NIAID
|
5R01AI089957-02
|
|
Novel antiviral activities of tumor necrosis factor-alpha
|
DUSTIN, LYNN
|
ROCKEFELLER UNIVERSITY
|
NY
|
$423,750
|
|
Hepatitis
|
2012
|
NIAID
|
5K23AI083099-03
|
|
CAUSES OF AND ASSOCIATIONS WITH DEATH DURING LONG TERM HAART IN AFRICA
|
HOFFMANN, CHRISTOPHER
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$134,325
|
|
Hepatitis
|
2012
|
NCI
|
5K24CA139570-03
|
|
A Multidisciplinary and Translational Approach to Hepatobiliary Malignancy
|
NELSON, DAVID
|
UNIVERSITY OF FLORIDA
|
FL
|
$186,940
|
|
Hepatitis
|
2012
|
NCI
|
5K25CA127524-05
|
|
Biomarker Discovery for Hepatitis C Progression using Machine Learning Techniques
|
SPRATT, HEIDI
|
UNIVERSITY OF TEXAS MEDICAL BR GALVESTON
|
TX
|
$133,197
|
|
Hepatitis
|
2012
|
NIAID
|
5R21AI088516-02
|
|
Natural Phenotypic Diversity of HCV NS3/4A Protease
|
GRETCH, DAVID
|
UNIVERSITY OF WASHINGTON
|
WA
|
$193,125
|
|
Hepatitis
|
2012
|
NIA
|
5K01AG034999-02
|
|
Aging with Chronic Viral Infections and the Impact on Innate Immune Responses
|
STOUT-DELGADO, HEATHER
|
LOVELACE BIOMEDICAL & ENVIRONMENTAL RES
|
NM
|
$137,430
|
|
Hepatitis
|
2012
|
NIAID
|
5R01AI079150-04
|
|
Cyclosporine, Cyclophilins and HCV Replication
|
TANG, HENGLI
|
FLORIDA STATE UNIVERSITY
|
FL
|
$321,298
|
|
Hepatitis
|
2012
|
RMAP
|
5R01GM095638-03
|
|
Engineered antibody fragments for cocrystallization with signal peptide peptidase
|
MAYNARD, JENNIFER
|
UNIVERSITY OF TEXAS AUSTIN
|
TX
|
$297,000
|
|
Hepatitis
|
2012
|
NIDDK
|
5R24DK085638-03
|
|
Genetic and Cellular Mechanisms of NAFLD and Hepatic Insulin Resistance
|
SHULMAN, GERALD
|
YALE UNIVERSITY
|
CT
|
$1,271,028
|
|
Hepatitis
|
2012
|
NIDA
|
5R01DA013324-14
|
|
Hepatitis C Pathogenesis and the Human Genome
|
THOMAS, DAVID
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$694,428
|
|
Hepatitis
|
2012
|
NIDA
|
1R01DA033673-01
|
|
Implementation of a Sexual Health Intervention for YMSM in Two Vietnamese Cities
|
GOLDSAMT, LLOYD
|
NATIONAL DEVELOPMENT & RES INSTITUTES
|
NY
|
$679,158
|
|
Hepatitis
|
2012
|
NIAID
|
5K08AI081544-04
|
|
HIV, Kupffer Cells, and HCV-related Liver Fibrosis
|
BALAGOPAL, ASHWIN
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$128,885
|
|
Hepatitis
|
2012
|
NCI
|
1F31CA167872-01
|
|
Characterization of novel regulators of amino acid-sensitive mTORC1 signaling
|
SCHWEITZER, LAWRENCE
|
MASSACHUSETTS INSTITUTE OF TECHNOLOGY
|
MA
|
$42,232
|
|
|
